Other LEXEO Programs
for the treatment of Metachromatic leukodystrophy
LXc-002 and LXc-003,
"Vectorized” antibody programs addressing Tauopathies including Alzheimer’s disease and Chronic traumatic encephalopathy.
LEXEO holds an exclusive option to research, develop and commercialize three late pre-clinical stage gene therapy product candidates in the liver-directed and cardiac hereditary disease areas, as well as an option on eight pre-clinical “vectorized” antibodies in the inflammation/allergy and oncology therapeutic areas addressing acquired diseases.